Feline Anaphylaxis and Acute Allergic Reactions (Vaccine-Associated and Other Causes)

Feline anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction that occurs when a sensitized cat is re-exposed to a specific antigen, triggering a massive and rapid release of inflammatory mediators. In cats, anaphylaxis most commonly occurs in the context of vaccine administration, insect stings, drug injections, or food antigens, with vaccine-associated reactions representing one of the most frequently documented triggers in clinical practice. Unlike dogs, cats exhibit a unique pattern of anaphylaxis predominantly involving the hepatic and gastrointestinal systems due to the liver being the primary shock organ in this species. Prompt recognition and emergency intervention are critical, as the condition can progress to cardiovascular collapse and death within minutes to hours if untreated.

Underlying Causes:

Feline anaphylaxis is triggered by a diverse array of antigens, including:

• ·Vaccines: Modified-live or killed virus vaccines (e.g., FVRCP combinations, rabies vaccines) are among the most commonly implicated triggers; polyvalent vaccines and adjuvanted vaccines appear to carry a higher risk of acute reactions
• ·Medications: Penicillins, cephalosporins, NSAIDs, opioids (particularly morphine), radiocontrast media, and blood products
• ·Insect venom: Hymenoptera stings (bees, wasps, hornets)
• ·Dietary antigens: Food allergens, particularly novel proteins in hypersensitive individuals
• ·Latex and environmental antigens: Rarely documented but possible in sensitized animals

Immunological Mechanism:

Classical anaphylaxis in cats follows a Type I (IgE-mediated) hypersensitivity mechanism. Upon initial antigen exposure (sensitization phase), antigen-presenting cells present the allergen to Th2 lymphocytes, which stimulate B cells to produce allergen-specific immunoglobulin E (IgE). These IgE antibodies bind to high-affinity Fc receptors (FcεRI) on the surface of mast cells and basophils throughout the body. Upon re-exposure to the same antigen (elicitation phase), cross-linking of bound IgE molecules triggers mast cell and basophil degranulation. This releases a large quantity of preformed and newly synthesized mediators, including:

• ·Histamine: The primary early mediator causing vasodilation, increased vascular permeability, smooth muscle contraction, and pruritus
• ·Prostaglandins and leukotrienes: Amplify and sustain vasoactive and bronchoconstrictor effects
• ·Platelet-activating factor (PAF): Contributes to cardiovascular collapse and microvascular damage
• ·Tryptase and other proteases: Cause tissue damage and activate complement pathways

Species-Specific Shock Pattern in Cats:

A critical distinction in cats is that the primary shock organ is the liver and gastrointestinal tract, not the lungs (as in dogs) or cardiovascular system (as in humans). Hepatic venous congestion occurs rapidly due to contraction of hepatic vascular smooth muscle, leading to portal hypertension, splanchnic pooling, and reduced cardiac preload. The result is a clinical syndrome dominated by gastrointestinal signs (vomiting, diarrhea), hepatic congestion, and cardiovascular collapse rather than the bronchospasm-predominant picture seen in humans and dogs.

Non-IgE-Mediated (Anaphylactoid) Reactions:

Some acute allergic-type reactions occur without prior sensitization through direct mast cell degranulation triggered by certain drugs (e.g., opioids, radiocontrast agents) or complement activation. These anaphylactoid reactions are clinically indistinguishable from true IgE-mediated anaphylaxis and require the same emergency management.

Feline anaphylaxis is primarily a clinical diagnosis based on the temporal association between antigen exposure and the acute onset of multisystem signs. A thorough history is paramount, including recent vaccinations (within the past 1–2 hours), drug administration, insect exposure, and dietary changes.

Clinical Assessment:

• ·Physical examination findings of acute onset facial edema, urticaria, vomiting, cardiovascular instability, and altered mentation in proximity to a known trigger are often sufficient for a working diagnosis
• ·Assessment of mucous membrane color, capillary refill time, pulse quality, and respiratory effort should be performed immediately

Laboratory Findings:

While laboratory testing should not delay emergency treatment, the following changes may be observed:

• ·

  Complete Blood Count (CBC):

  • ·HCT (Hematocrit): May be elevated (hemoconcentration) due to plasma extravasation into tissues, or low if concurrent hemorrhage occurs
  • ·PLT (Platelets): May be reduced (thrombocytopenia) in severe cases due to consumption and platelet activation by PAF
  • ·WBC: Variable; initial leukopenia (due to margination) may be followed by leukocytosis; eosinophilia may be noted in chronic atopic cases but is usually absent in acute anaphylaxis
• ·

  Serum Biochemistry:

  • ·ALT (Alanine Aminotransferase): Often markedly elevated due to hepatic congestion and ischemic hepatocyte damage, reflecting the liver as the primary shock organ
  • ·BUN and CREA (Blood Urea Nitrogen / Creatinine): May increase due to reduced renal perfusion (pre-renal azotemia) in hypotensive states
  • ·ALB (Albumin): Can decrease acutely due to vascular leakage and protein loss into the interstitium
  • ·TBIL (Total Bilirubin): May be mildly elevated secondary to hepatic congestion and reduced hepatic clearance
  • ·GLOB (Globulins): Generally non-diagnostic in the acute phase, though pre-existing allergic disease may show elevated globulin fractions
• ·

  Blood Pressure Monitoring: Hypotension (systolic <90 mmHg) is expected in moderate-to-severe cases and should be monitored continuously

• ·

  Blood Gas Analysis: Metabolic acidosis (lactic acidosis) may be present due to poor tissue perfusion; pulse oximetry may reveal hypoxemia in cases with respiratory compromise

Tryptase Assay:

Measurement of serum mast cell tryptase is a validated biomarker for anaphylaxis in humans and has been described in veterinary species. Although not yet widely available in clinical feline practice, elevated tryptase levels support mast cell degranulation and can help retrospectively confirm anaphylaxis in ambiguous cases.

Differential Diagnoses to Consider:

• ·Acute pancreatitis (vomiting, abdominal pain, elevated lipase)
• ·Vasovagal syncope (absence of urticaria, angioedema, or allergen exposure)
• ·Cardiac arrhythmias/syncope
• ·Acute upper respiratory obstruction (foreign body, laryngeal mass)
• ·Septic shock
• ·Acute toxin ingestion

Anaphylaxis is a veterinary emergency requiring immediate and aggressive intervention. Treatment should follow a stepwise protocol addressing airway, breathing, circulation, and anaphylaxis-specific mediator blockade.

1. Immediate First-Line Treatment — Epinephrine (Adrenaline):

Epinephrine is the cornerstone of anaphylaxis treatment and should be administered without delay.

• ·Dose: 0.01 mg/kg of 1:1,000 (1 mg/mL) epinephrine, administered intramuscularly (IM) into the epaxial muscle or quadriceps; IM administration provides faster and more reliable absorption than subcutaneous injection
• ·Alternatively, IV epinephrine (1:10,000 dilution, administered slowly) may be used in cardiovascular collapse, with caution due to risk of arrhythmia
• ·Epinephrine acts through α1-adrenergic receptors (vasoconstriction, reversal of hypotension) and β1/β2-adrenergic receptors (increased cardiac output, bronchodilation, inhibition of mast cell degranulation)
• ·Repeat dosing at 5–15 minute intervals if initial response is inadequate

2. Airway and Oxygen Support:

• ·Supplemental oxygen via flow-by, mask, or oxygen cage should be provided immediately
• ·Endotracheal intubation may be necessary if laryngeal edema is causing severe upper airway obstruction
• ·Mechanical ventilation may be required in cases with respiratory failure

3. Intravenous Fluid Therapy:

• ·Rapid IV access should be established; crystalloid fluid resuscitation (e.g., 0.9% NaCl or Plasma-Lyte) administered as a bolus (10–20 mL/kg IV over 10–20 minutes) to restore circulating volume
• ·Colloids (e.g., hetastarch) may be used in combination with crystalloids to address oncotic pressure loss secondary to plasma leakage
• ·Fluid therapy should be titrated to response (blood pressure, mucous membrane color, pulse quality)

4. Antihistamines:

• ·H1 antagonists: Diphenhydramine (2–4 mg/kg IM or IV slowly) to reduce histamine-mediated effects; should be considered adjunctive therapy after epinephrine
• ·H2 antagonists: Famotidine or ranitidine may be added to address gastric acid secretion and GI signs
• ·Note: Antihistamines are not substitutes for epinephrine and should never delay its administration

5. Glucocorticoids:

• ·Dexamethasone sodium phosphate (0.1–0.2 mg/kg IV) or prednisolone sodium succinate (10–30 mg/kg IV in severe cases)
• ·Glucocorticoids are indicated to prevent or attenuate the biphasic reaction (a second wave of anaphylaxis occurring 4–24 hours after initial resolution) and to reduce prolonged inflammation
• ·Onset of action is delayed (30–60 minutes), so glucocorticoids should never replace epinephrine as first-line therapy

6. Bronchodilators:

• ·Nebulized or IV terbutaline (0.01 mg/kg SC or IM) may be used for persistent bronchospasm or respiratory distress unresponsive to epinephrine
• ·Salbutamol (albuterol) via nebulization or metered-dose inhaler can also be employed

7. Vasopressors:

• ·Dopamine (5–15 mcg/kg/min CRI) or norepinephrine CRI may be required for persistent hypotension refractory to epinephrine and fluid therapy

8. Monitoring and Hospitalization:

• ·Patients should be monitored continuously for a minimum of 4–6 hours post-reaction; overnight hospitalization is recommended for moderate-to-severe cases due to biphasic reaction risk
• ·ECG monitoring for arrhythmias, blood pressure monitoring, and reassessment of laboratory parameters are advised

Post-Stabilization Care:

• ·Oral antihistamines and a short course of oral prednisolone (1–2 mg/kg/day for 3–5 days) are often prescribed upon discharge to reduce the risk of recurrence
• ·Owner education regarding avoidance of the identified trigger is essential

The prognosis for feline anaphylaxis is highly variable and directly correlates with the speed of recognition, proximity to veterinary care, and the severity of the initial reaction.

Mild-to-Moderate Reactions (Localized angioedema, urticaria, mild GI signs):

• ·Prognosis is excellent with prompt appropriate treatment; the vast majority of cats with vaccine-associated urticaria or facial swelling recover fully within hours of antihistamine and/or steroid administration
• ·Mortality in mild cases is very low, generally estimated at less than 5%

Moderate-to-Severe Reactions (Cardiovascular compromise, hypotension, systemic signs):

• ·Prognosis is guarded to fair with aggressive emergency intervention; most cats that receive epinephrine and fluid resuscitation in a timely manner survive
• ·Delayed treatment significantly worsens outcome; cats that present in cardiovascular collapse with unresponsive hypotension carry a poor prognosis

Overall Mortality Considerations:

• ·Specific peer-reviewed survival statistics for feline anaphylaxis are limited in the available veterinary literature; overall case-fatality rates in anaphylaxis treated promptly in a clinical setting are estimated at approximately 10–20% for systemic reactions across veterinary species
• ·The biphasic reaction, occurring 4–24 hours after the initial event, represents an important secondary mortality risk; patients that are discharged prematurely before adequate monitoring windows have elapsed are at risk of recurrence-related fatality
• ·Cats experiencing anaphylaxis from intravenous drug administration (e.g., chemotherapy agents, blood products) are at higher risk of severe reactions compared to vaccine-associated events due to direct systemic antigen delivery

Data Limitations: Data on long-term prognosis and precise species-specific survival statistics for feline anaphylaxis are limited in current veterinary literature; no peer-reviewed survival statistics specific to cats were identified in the references available for this entry. The estimates provided above are based on general veterinary emergency medicine principles and clinical expert consensus.

Prevention strategies are tailored to the identified or suspected trigger and the clinical history of the individual patient.

Vaccine-Associated Reactions — Pre-vaccination Precautions:

• ·A detailed history of prior vaccine reactions should be obtained before every vaccination visit; cats with a history of prior vaccine-associated reactions should be identified and flagged in their medical records
• ·Pre-medication protocols for high-risk cats: administration of diphenhydramine (2–4 mg/kg IM) approximately 15–30 minutes before vaccination, combined with a low-dose glucocorticoid, has been used to reduce the incidence and severity of reactions; however, evidence supporting routine pre-medication in all cats is limited, and decisions should be individualized
• ·Vaccine formulations: consider switching to a non-adjuvanted vaccine formulation in cats that have previously reacted to adjuvanted products, as adjuvants (particularly aluminum salts) are implicated in potentiating immune activation
• ·Post-vaccination observation: all vaccinated cats should be observed in the veterinary clinic for a minimum of 15–30 minutes following injection; cats with prior reactions should be monitored for 60 minutes
• ·Avoid administering multiple vaccines simultaneously in high-risk cats; staggering vaccines over separate visits reduces antigen load and allows for reaction attribution

Minimizing Risk from Other Triggers:

• ·Drug hypersensitivity: maintain a detailed allergy record for each patient; avoid re-administration of drugs associated with prior adverse reactions; use alternative drug classes where possible
• ·Insect venom: indoor housing reduces exposure to stinging insects; owners of previously anaphylactic cats should be counseled on keeping emergency epinephrine available
• ·Dietary antigens: strict avoidance of identified food allergens; use hydrolyzed or novel protein diets under veterinary guidance for cats with confirmed food hypersensitivity

Emergency Preparedness:

• ·Veterinary clinics administering vaccines or injectable medications should maintain a stocked anaphylaxis emergency kit including epinephrine (1:1,000), diphenhydramine, dexamethasone, IV fluids, IV catheters, and oxygen
• ·Owner education: clients should be informed of the signs of delayed anaphylaxis and instructed to return immediately if signs develop within 24 hours of vaccination or drug administration

Risk-Benefit Assessment:

• ·In cats with a history of severe anaphylaxis to a specific vaccine, the decision to re-vaccinate should involve a thorough risk-benefit discussion; in some cases (e.g., indoor-only cats with demonstrated immunity titers), vaccination may be deferred in favor of serological titer testing to assess protective immunity